@article {757,
	title = {Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential},
	journal = {Journal of Biological Inorganic Chemistry},
	volume = {8},
	number = {1-2},
	year = {2003},
	note = {ISI Document Delivery No.: 638ACTimes Cited: 62Cited Reference Count: 52},
	month = {Jan},
	pages = {66-74},
	type = {Article},
	abstract = {A series of 2-alkyl-3-hydroxy-4-pyrone oxovanadium(IV) compounds has been synthesized, characterized, and tested for bioactivity as potential insulin-enhancing agents. The vanadyl complexes, bis(maltolato)oxovanadium(IV), BMOV, bis(ethylmaltolato)oxovanadium(IV), BEOV, and bis(isopropylmaltolato) oxovanadium(IV), BIOV, were compared against vanadyl sulfate for glucose-lowering ability, when administered i.p. to STZ-diabetic rats, at a one-time dose of 0.1 mmol kg(-1) body weight. Blood levels of vanadium were determined at regular intervals, to 72 h, following i.p. injection. All complexes tested exceeded vanadyl sulfate in glucose-lowering ability; this effect was not correlated, however, with blood vanadium levels. Analysis of the pharmacokinetics of the disappearance of [ethyl-1-C-14]BEOV after an oral gavage dose (50 mg kg(-1), 0.144 mmol kg(-1), in a 10 mL kg(-1) volume of 1\% CMC solution) indicated clearly that metal ion-ligand dissociation took place relatively soon after oral ingestion of the complex. Half-lives of fast phase uptake and slow phase disappearance for C-14 and V were calculated from a two-compartment model for whole blood, plasma, liver, kidney, bone, small intestine, and lung, ranging from 17 min (t(1/2)alpha for C-14, liver) to 30 days (t(1/2)beta for V, bone). Curves of disappearance of plasma and whole blood C-14 and V diverged dramatically within the first hour after administration of the vanadium complex.},
	keywords = {ABSORPTION, BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, CHEMISTRY, COORDINATION MODE, ETHYL MALTOL, IN-VITRO, INSULIN MIMETIC AGENT, insulin-enhancing activity, pharmacokinetics, PHOSPHATIDYLINOSITOL 3-KINASE, POLYMORPHIC FORMS, RATS, STZ-diabetic rat, vanadyl pyrone complexes},
	isbn = {0949-8257},
	url = {<Go to ISI>://000180545000008},
	author = {Thompson, K. H. and Liboiron, B. D. and Bellman, Yskdd and Setyawati, I. A. and Patrick, B. O. and Karunaratne, V. and Rawji, G. and Wheeler, J. and Sutton, K. and Bhanot, S. and Cassidy, C. and McNeill, J. H. and Yuen, V. G. and Orvig, Chris}
}
@article {742,
	title = {Vanadyl-thiazolidinedione combination agents for diabetes therapy},
	journal = {Bioconjugate Chemistry},
	volume = {14},
	number = {1},
	year = {2003},
	note = {ISI Document Delivery No.: 637YYTimes Cited: 23Cited Reference Count: 42},
	month = {Jan-Feb},
	pages = {212-221},
	type = {Article},
	abstract = {A series of vanadium compounds, chelated by ligands containing a thiazolidinedione moiety as an additional insulin-enhancing component, were produced in this study to create potentially synergistic compounds. A set of four bifunctional ligand precursors were synthesized: (+/-)-5-4-[(5-hydroxy-4-oxo-4H-pyran-2-ylmethyl)amino]benzylthiazolidi ne-2,4-dione (HL1), (+/-)-5-4-[5-hydroxy-1-methyl-4-oxo-1,4-dihydro-pyridin-2-ylmethyl)amin o]benzylthiazolidine-2,4-dione (HL2) 5-[4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzylidenelthiazolidine-2,4- dione (HL1), and (+/-)-5-4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzyl]thiazolidine-2,4 -dione (HL4), each containing a metal chelating portion as well as a thiazolidinedione moiety. From this set of ligand precursors, air-stable VO(L-1)(2), VO(L-3)(2), and VO(L-4)(2) were prepared. The four ligand precursors and three complexes were tested for insulin-enhancing potential in STZ-diabetic rats and compared to rosiglitazone and BMOV, respectively. Both the ligand precursors HL1 and HL3 showed enhanced activity compared with that of rosiglitazone. The complex VO(L-3)(2) showed the most efficacious hypoglycemic effects in this study; however, neither additive nor synergistic effects were observed using this acute animal model.},
	keywords = {AGENT, ANTIHYPERGLYCEMIC, BIOLOGICAL-ACTIVITY, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, COMPLEXES, DERIVATIVES, GLUCOSE-LOWERING PROPERTIES, INSULIN MIMETIC AGENT, RAT ADIPOCYTES, TROGLITAZONE},
	isbn = {1043-1802},
	url = {<Go to ISI>://000180542400025},
	author = {Storr, T. and Mitchell, D. and Buglyo, P. and Thompson, K. H. and Yuen, V. G. and McNeill, J. H. and Orvig, Chris}
}
@article {4413,
	title = {[(mu-OCH3)VO(ma)](2), a strongly antiferromagnetic oxovanadium(IV) dimer},
	journal = {Inorganic Chemistry},
	volume = {37},
	number = {12},
	year = {1998},
	note = {ISI Document Delivery No.: ZV268Times Cited: 24Cited Reference Count: 17},
	month = {Jun},
	pages = {3119-3121},
	type = {Article},
	keywords = {BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, COMPLEXES, CRYSTAL-STRUCTURE, INSULIN MIMETIC AGENT, SPECTROSCOPY},
	isbn = {0020-1669},
	url = {<Go to ISI>://000074287600048},
	author = {Sun, Y. and Melchior, M. and Summers, D. A. and Thompson, R. C. and Rettig, S. J. and Orvig, Chris}
}
@article {4413,
	title = {[(mu-OCH3)VO(ma)](2), a strongly antiferromagnetic oxovanadium(IV) dimer},
	journal = {Inorganic Chemistry},
	volume = {37},
	number = {12},
	year = {1998},
	note = {ISI Document Delivery No.: ZV268Times Cited: 24Cited Reference Count: 17},
	month = {Jun},
	pages = {3119-3121},
	type = {Article},
	keywords = {BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, COMPLEXES, CRYSTAL-STRUCTURE, INSULIN MIMETIC AGENT, SPECTROSCOPY},
	isbn = {0020-1669},
	url = {<Go to ISI>://000074287600048},
	author = {Sun, Y. and Melchior, M. and Summers, D. A. and Thompson, R. C. and Rettig, S. J. and Orvig, Chris}
}
@article {4167,
	title = {Glucose-lowering properties of vanadium compounds: Comparison of coordination complexes with maltol or kojic acid as ligands},
	journal = {Journal of Inorganic Biochemistry},
	volume = {68},
	number = {2},
	year = {1997},
	note = {ISI Document Delivery No.: YA963Times Cited: 72Cited Reference Count: 44},
	month = {Nov},
	pages = {109-116},
	type = {Article},
	abstract = {Bis(kojato)oxovanadium(IV) [abbreviated VO(ka)(2)], a close chemical analog of the insulin-mimetic lead compound bis(maltolato) oxovanadium (IV) - abbreviated BMOV or VO(ma)(2) - is reported and its reaction chemistry and insulin-mimetic properties are presented. VO(ka)(2) [log K-1 = 7.61(10), log K-2 = 6.89(6), log beta(2) = 14.50(16)] has a reaction chemistry which directly parallels that of VO(ma)(2). In aqueous solution it is more slowly oxidized by molecular oxygen to [VO2(ka)(2)](-) than is VO(ma)(2) to [VO2(ma)(2)](-). Variable pH electrochemistry and variable pH V-51 NMR of solutions of VO(Ka)(2) are presented and contrasted with the corresponding results for VO(ma)(2). Time course studies (24 hr) in Sn-diabetic rats following the oral or ip administration of VO(ka)(2), VO(ma)(2), VO2+ (vanadyl) as vanadyl sulfate (VOSO4), and [VO2(ma)(2)](-) as its [NH4](+) salt have been performed, as have chronic oral studies comparing VO(ka)(2) and VO(ma)(2) over a six week period. lit all studies, the most potent form of vanadium was the neutrally charged water soluble, complex VO(ma)(2). (C) 1997 Elsevier Science Inc.},
	keywords = {ALUMINUM(III), BIOINORGANIC CHEMISTRY, BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, DIABETIC RATS, INHIBITOR, INSULIN MIMETIC AGENT, ISOLATED RAT ADIPOCYTES, LABILE, METABOLISM, OXOVANADATES, VANADATE},
	isbn = {0162-0134},
	url = {<Go to ISI>://A1997YA96300005},
	author = {Yuen, V. G. and Caravan, P. and Gelmini, L. and Glover, N. and McNeill, J. H. and Setyawati, I. A. and Zhou, Y. and Orvig, Chris}
}
